Physician profile
Grace Ryu
NPI 1215907480
$5,349.34
in general payments reported to CMS, 2019-2025
26 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $191 · 2021: $247 · 2022: $402 · 2023: $894 · 2024: $1,169 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,255 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,254.60 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,299.96 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $958.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $783.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $633.85 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $335.87 | 2019-2025 | Dupixent |
| Amgen INC. | $234.28 | 2023-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $180.18 | 2019-2025 | |
| Optinose US, INC. | $106.18 | 2022-2025 | |
| Pfizer INC. | $105.32 | 2023-2025 | |
| Kaleo, INC. | $97.06 | 2020-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $96.69 | 2024-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $84.09 | 2023-2025 | Cuvitru, Eohilia |
| Biocryst US Sales Co., LLC | $64.01 | 2023-2025 | Orladeyo |
| Genentech USA, INC. | $63.93 | 2024-2025 | Xolair |
| Grifols USA, LLC | $63.71 | 2024-2025 | Xembify |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $38.18 | 2020 | |
| Pharming Healthcare, INC. | $37.43 | 2023-2024 | Ruconest |
| Greer Laboratories, INC. | $28.81 | 2025 | Oralair |
| Ionis Pharmaceuticals, INC. | $22.60 | 2025 | Dawnzera |
| Covis Pharma Gmbh | $19.61 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.20 | 2025 | Xhance |
| Ars Pharmaceuticals Operations, INC. | $17.10 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $16.80 | 2025 | Nemluvio |
| Azurity Pharmaceuticals, INC. | $16.00 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $15.33 | 2023 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Ryu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.